• Visit the USI website
  • Go back to the homepage

Institute for Research in Biomedicine
Istituto di Ricerca in Biomedicina

Via Vincenzo Vela 6 - CH-6500 Bellinzona
Tel. +41 91 820 0300 - Fax +41 91 820 0302 - info [at] irb [dot] usi [dot] ch

Neutrophil subtypes: distinct cellular targets for therapeutic intervention (TANTUMorNEUVACCINE)

Hosting laboratory: Infezione ed immunità
Santiago F. González
Research area:

H2020-MSCA-IF-2016

Duration: 01.10.2017 to 30.09.2021

In cancer immunotherapy and vaccine field, considerable efforts have been invested to optimize the induction of effector T cells that, by recognizing tumor-specific or pathogen-associated antigens, control tumor cells or infections. Preserving effector T cell function is a major focus of cancer immunotherapy approaches for clinical trials, as is the development of strategies to target regulatory T cells (Tregs) that directly control T cell hypo-responsiveness. In the vaccine field, on the other hand, several strategies have been developed to improve T cell immunogenicity to heterologous antigens expressed by viral vectors. Especially for HIV viral vectors, new vaccine approaches have yielded promising results in primates, although effectiveness was limited in human clinical trials so far.
Tumor-associated neutrophils (TAN) participate in the control of human tumor progression. If and how TAN interact with effector Tregs at distinct tumor stages remains to be determined. TAN signals that may regulate the functional state of tumor T cells must be defined. It is also not known whether Tregs interact with TAN and facilitate their functional switch from antito pro- tumorigenic state.
Distinct neutrophil subtypes are recruited as a result of pro-inflammatory environment during virus infection. Study of the mechanism of neutrophil-dependent control of T cell subset responses to virus-delivered antigens would be of major interest for the generation of viral-based vaccines. The ability of neutrophil subtypes to interact with T cells must be defined to improve the virus-based vaccine efficacy.
Our studies could provide:
• new treatment strategies that prevent TAN dysfunction, Tregs activation and subsequent effector T cell hyporesponsiveness, and thus increase the effectiveness of cancer immunotherapy
• new vaccine approaches to modulate neutrophil subtypes responses to improve antigen-specific T cell responses, and thus increase the effectiveness of HIV vaccines.